Clinical Roundup NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves new alternative standard related to mammography report assessments November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves revumenib for r/r acute leukemia with a KMT2A translocation November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves first companion diagnostic for lung cancer drug November 22, 2024Vol.50 No.44
Regulatory News Ready or not, AI-based decision support tools are entering oncology clinicsRegulators and health systems must adapt November 15, 2024Vol.50 No.43By McKenzie Prillaman
Drugs & Targets FDA approves Aucatzyl for adults with r/r B-cell precursor ALL November 15, 2024Vol.50 No.43
Drugs & Targets FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients November 08, 2024Vol.50 No.42
Regulatory News At his 25-year “anniversary party,” Pazdur invites Califf and past FDA commissioners to talk about political interference November 01, 2024Vol.50 No.41By Claire Marie Porter
